Ann_Oncology - Preoperative PET/CT in early-stage breast cancer

Preoperative PET/CT in early-stage breast cancer

 Authors

Abstract

Background The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer.

Patients and methods A total of 103 consecutive patients with newly diagnosed operable breast cancer with tumors ≥2 cm were independently examined preoperatively with conventional assessment (mammography, breast/axillary ultrasound, chest X-ray and blood samples) and PET/CT with no prior knowledge of the other.

Results PET/CT identified a primary tumor in all but three patients (97%). PET/CT solely detected distant metastases (ovary, bones and lung) in 6 patients and new primary cancers (ovary, lung) in another two patients, as well as 12 cases of extra-axillary lymph node involvement. In 15 patients (15%), extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 14% (14/103) and ultimately a modification of planned treatment in 8% (8/103) of patients.......,

http://m.annonc.oxfordjournals.org/content/23/9/2277.short?rss=1

Sent from my iPhone

Announcing launch of new and improved search functionality for The Cochrane Library | The Cochrane Collaboration

http://www.cochrane.org/news/tags/authors/announcing-launch-new-and-improved-search-functionality-cochrane-library


Sent from my iPhone

ovarian cancer - Routes of spread (metastasis) in ovarian cancer - pics

Seth's Blog: Persistence and possibility

http://sethgodin.typepad.com/seths_blog/2012/08/persistence-and-possibility.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+typepad%2Fsethsmainblog+%28Seth%27s+Blog%29&utm_content=Google+Reader

ICGC Data Portal - International Cancer Genome (Canadian site)

ICGC Data Portal
 

ICGC Dataset Version 8 (March 15^th, 2012)

Cancer Projects: 29
Total Donors: 3,561

Clinical Oncology News - The Paradox of Increased Efficacy and End-of-Life Care

Clinical Oncology News - The Paradox of Increased Efficacy and End-of-Life Care

 This commentary focuses on the complex and often emotionally charged conflict between a patient’s desire to “fight the cancer” and his or her unquestionably valid need to focus on end-of-life issues at some point in time.

Clinical Oncology News - Randomized Phase II trials: A Pragmatic Way To Inform Clinical Practice

Clinical Oncology News - Randomized Phase II trials: A Pragmatic Way To Inform Clinical Practice

.....
Consider, for example, the recent report on the biological activity of single-agent, nanoparticle albumin-bound paclitaxel in the second-line treatment of epithelial ovarian cancer.¹ This nonrandomized study, conducted by the Gynecologic Oncology Group, revealed an objective response rate of 23%, similar to that previously reported with the far less expensive generic paclitaxel.^2,3
But is it possible that this agent is actually superior to paclitaxel in that treatment with nanoparticle albumin-bound paclitaxel achieves a similar degree of objective clinical benefit (e.g., degree of tumor shrinkage and delay in time to progression) but with a measurably more favorable toxicity profile that includes a substantially reduced risk for peripheral neuropathy?
Unfortunately, in the complete absence of data from a randomized trial, the answer to this specific question will simply be unknown because any suggested “superior” outcomes may solely reflect the inadvertent selection bias resulting from the favorable baseline clinical features inherent in all nonrandomized studies........

Clinical Oncology News - The Underreported Cardiac Toxicity of Anticancer Drugs

Clinical Oncology News - The Underreported Cardiac Toxicity of Anticancer Drugs

Ten-Year Relative Survival for Epithelial ovarian cancer

Ten-Year Relative Survival for Epithelial Ovarian Cancer Gynecol. 2012 Sep;120(3):612-618.

Abstract

OBJECTIVE: Most patients with epithelial ovarian cancer who are alive at 5 years have active disease. Thus, 10-year survival rather than 5-year survival may be a more appropriate endpoint. Relative survival adjusts for the general survival of the United States population for that race, sex, age, and date at which the diagnosis was coded. Our objective was to estimate relative survival in epithelial ovarian cancer over the course of 10 years.

METHODS: Using the Surveillance, Epidemiology and End Results 1995-2007 database, epithelial ovarian cancer cases were identified. Using the actuarial life table method, relative survival over the course of 10 years was calculated, stratified by stage, classification of residence, surgery as the first course of treatment, race, and age.

RESULTS: There were 40,692 patients who met inclusion criteria. The overall relative survival was 65%, 44%, and 36% at 2, 5, and 10 years, respectively. The slope of decline in relative survival was reduced for years 5-10 as compared with years 1-5 after diagnosis. Relative survival at 5 years was 89%, 70%, 36%, and 17%, and at 10 years relative survival was 84%, 59%, 23%, and 8% for stages I, II III, and IV, respectively. At all stages, patients with nonsurgical primary treatment and those with advanced age had reduced relative survival.

CONCLUSIONS: The 10-year relative survival for stage III is higher than expected. This information provides the physician and the patient with more accurate prognostic information.

http://www.ncbi.nlm.nih.gov/m/pubmed/22914471/?i=15&from=ovarian%20cancer

Sent from my iPhone

FDA MedWatch - CareFusion Alaris Pump Module Model 8100: Class I Recall - Motor Stalls During Infusion

From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: 25 August, 2012 8:42:31 AM EDT

Subject: U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

Subject: FDA MedWatch - CareFusion Alaris Pump Module Model 8100: Class I Recall - Motor Stalls During Infusion

Synchronous double primary ovarian tumor in situ]. (clear cell/endometrioid)

http://www.ncbi.nlm.nih.gov/m/pubmed/22916642/


Sent from my iPhone

Genetic markers for ovarian cancer risk: are we close to seeing a clinical impact?

http://www.futuremedicine.com/doi/pdfplus/10.2217/pme.12.58


Sent from my iPhone

Seth's Blog: Questions we ask before we trust your new idea

http://sethgodin.typepad.com/seths_blog/2012/08/questions-we-ask-before-we-trust-your-new-idea.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+typepad%2Fsethsmainblog+%28Seth%27s+Blog%29&utm_content=Google+Reader


Sent from my iPhone

JCO: Opioid Prescription After Pain Assessment: A Population-Based Cohort of Elderly Patients With Cancer

http://m.jco.ascopubs.org/content/30/10/1095.abstract


Sent from my iPhone

What does the patient know about quality? (no abstract)

http://www.ncbi.nlm.nih.gov/m/pubmed/22918180/


Sent from my iPhone

Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study.

Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study.

http://www.ncbi.nlm.nih.gov/m/pubmed/22495683/

Sent from my iPhone

JNM | Oncologic 18F-FDG PET/CT: Referring Physicians’ Point of View

http://m.jnm.snmjournals.org/content/early/2012/08/23/jnumed.111.102228.abstract

Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis.

http://www.ncbi.nlm.nih.gov/m/pubmed/22915981/?i=3&from=ovarian%20cancer


Sent from my iPhone

SLOCA event

http://www.sloca.org/news/blog/2012/08/16/sloca-plans-awareness-seminar


Sent from my iPhone

Adjuvant Chemotherapy for Stage I Ovarian Clear Cell Carcinoma: Is it Necessary for Stage IA?

http://mobile.journals.lww.com/ijgc/_layouts/oaks.journals.mobile/abstractviewer.aspx?year=2012&issue=09000&article=00009


Sent from my iPhone

ScienceDirect.com - European Journal of Cancer - Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials

http://www.sciencedirect.com/science/article/pii/S0959804912006065

Sent from my iPhone

JMIR--Are Personal Health Records Safe? A Review of Free Web-Accessible Personal Health Record Privacy Policies | Carrión Señor | Journal of Medical Internet Research

http://www.jmir.org/2012/4/e114/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+JMedInternetRes+%28Journal+of+Medical+Internet+Research+%28atom%29%29&utm_content=Google+Reader

Safety Alerts for Human Medical Products > CareFusion 303, Alaris Pump Module, Model 8100: Class I Recall - Potential for Pump Malfunction To Stop Infusion

...BACKGROUND: The pump module is intended for healthcare facilities that use infusion for the delivery of fluids, drugs, blood, and blood products using continuous or intermittent delivery through intravenous, intra-arterial, subcutaneous, epidural, enteral, or irrigation of fluid spaces routes of administration. The pump module is used for adults, children, and newborns...

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm316637.htm?source=govdelivery


Sent from my iPhone

FTC clears Facebook's acquisition of Instagram

http://reut.rs/PHbkMA

Search Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening.

Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening.

http://www.ncbi.nlm.nih.gov/m/pubmed/22911634/?i=8&from=ovarian

Sent from my iPhone

Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).

Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).

http://www.ncbi.nlm.nih.gov/m/pubmed/22911637/?i=7&from=ovarian

Sent from my iPhone

Do Biopsies Spread Cancer? -- SAN DIEGO, Aug. 23, 2012 /PRNewswire/ --

http://m.prnewswire.com/news-releases/do-biopsies-spread-cancer-167177565.html


Sent from my iPhone

Blog: truth, hope and communication...

....,Patients want us to be truthful, compassionate, and clear about their prognosis and want to know that we will be there with them every step of the way. Rather than taking away hope, being honest with our patients provides them with the necessary information to help them redefine hope, even if cure is not possible.

http://www.google.ca/reader/i/?source=mog&hl=en&gl=ca


Sent from my iPhone

CaPP3: progress towards a launch in 2013 - CaPP3 Cancer Prevention Programme - Lynch Syndrome/aspirin

http://www.capp3.org/our-blog/capp3-progress-towards-a-launch-in-2013.aspx


Sent from my iPhone

THEONCOLOGIST : Doublet Chemotherapy in the Elderly Patient with Ovarian Cancer

http://m.theoncologist.alphamedpress.org/content/early/2012/08/21/theoncologist.2012-0155.short?rss=1


Sent from my iPhone

Oncolytic virotherapy for ovarian cancer

http://www.dovepress.com/oncolytic-virotherapy-for-ovarian-cancer-peer-reviewed-article-OV


Sent from my iPhone

Patients' perception of error during craniotomy for brain tumour and their attitudes towards pre-operative discussion of error: a qualitative study.

http://www.ncbi.nlm.nih.gov/m/pubmed/22122712/


Sent from my iPhone

Ovarian cancer study to look at lifestyle | The Australian

....More than 1000 newly diagnosed Australian women will participate in the five-year study.

"We are trying to answer the question that almost every woman with ovarian cancer asks - what can I do to help beat this disease?" said Associate Professor Penny Webb from the institute's gynaecological cancers group.....


http://m.theaustralian.com.au/news/breaking-news/ovarian-cancer-study-to-look-at-lifestyle/story-fn3dxiwe-1226456389727


Sent from my iPhone

IJMS | Free Full-Text | Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125

http://www.mdpi.com/1422-0067/13/8/10568

LRP1B Deletion in High-Grade Serous Ova - PubMed Mobile

LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin.

http://www.ncbi.nlm.nih.gov/m/pubmed/22896685/

Marti Hughes

Martha L. Hughes

February 7, 1948 - August 20, 2012

http://www.schoedinger.com/obituaries/Martha-Hughes/

CDC - Ovarian Cancer - Treatment

http://m.cdc.gov/en/HealthSafetyTopics/DiseasesConditions/Cancer/Gynecologic/Ovarian/treatment


Sent from my iPhone

Head of Education and Supportive Services with Target Ovarian Cancer | 348339 (job posting UK)

• Location: Islington, London
• Contract type: Permanent
• Salary: £30,400 for 30 hours per week (£38,000 pro rata)
• Date posted: 22 August 2012
• Recruiter: Target Ovarian Cancer

http://m.jobs.thirdsector.co.uk/job/348339/?TrackID=55&CookieTest=True

Sent from my iPhone

Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial

http://www.nature.com/bjc/journal/v107/n5/full/bjc2012336a.html


Sent from my iPhone

Ann_Oncology - The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

http://m.annonc.oxfordjournals.org/content/early/2012/08/21/annonc.mds203.short?rss=1?rss=1?rss=1


Sent from my iPhone

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

http://www.ncbi.nlm.nih.gov/m/pubmed/21892704/


Sent from my iPhone

New medical technology improves image quality and reduces radiation PET/MRI

http://www.news-medical.net/post.aspx?id=5efbfab4-a612-47ad-8af0-75c7e4b6fc3c


Sent from my iPhone

Taxanes for Ovarian Cancer during Pregn - PubMed Mobile

Taxanes for Ovarian Cancer during Pregnancy: A Systematic Review.

http://www.ncbi.nlm.nih.gov/m/pubmed/22907101/

Sent from my iPhone

Adnexal masses suspected to be benign treated with laparoscopy

Adnexal masses suspected to be benign treated with laparoscopy.

http://www.ncbi.nlm.nih.gov/m/pubmed/22906334/?i=7&from=ovarian%20cancer

Many Americans see specialists for primary care: study

Many Americans see specialists for primary care: study
http://www.reuters.com/article/idUSBRE87K13W20120821

A Patient “Disrespected” - Cancer Network

A qualitative study on the term CAM: is there a need to reinvent the wheel?

Conclusions: CAM and other related terms could be used more effectively, provided they are used in the proper context. It appears difficult for the time being to reach a consensus on the definition of the term CAM due to the uncertainty of the positioning of CAM in the contemporary healthcare systems. While umbrella terms such as CAM and IHC are useful in the context of research, policy making and education, relevant stakeholders should limit the use of those 

A qualitative study on the term CAM: is there a need to reinvent the wheel?

Background:
As complementary and alternative medicine (CAM) has developed extensively, uncertainty about the appropriateness of the terms CAM and other CAM-related terms has grown both in the research and practice communities. Various terms and definitions have been proposed over the last three decades, highlighting how little agreement exits in the field. Contextual use of current terms and their respective definitions needs to be discussed and addressed.
Methods:
Relying upon the results of a large international Delphi survey on the adequacy of the term CAM, a focus group of 13 international experts in the field of CAM was held. A forum was also set up for 28 international experts to discuss and refine proposed definitions of both CAM and integrative healthcare (IHC) terms. Audio recordings of the meeting and forum discussion threads were analyzed using interpretive description.
Results:
Multiple terms to describe the therapies, products, and disciplines often referred to as CAM, were considered. Even though participants generally agreed there is a lack of optimal definitions for popular CAM-related umbrella terms and that all terms that have so far been introduced are to some extent problematic, CAM and IHC remained the most popular and accepted terms by far. The names of the specific disciplines were also deemed adequate in certain contexts. Focus group participants clarified the context in which those three terms are appropriate. Existing and emergent definitions of both CAM and integrative healthcare terms were discussed.

Conclusions:
CAM and other related terms could be used more effectively, provided they are used in the proper context. It appears difficult for the time being to reach a consensus on the definition of the term CAM due to the uncertainty of the positioning of CAM in the contemporary healthcare systems. While umbrella terms such as CAM and IHC are useful in the context of research, policy making and education, relevant stakeholders should limit the use of those terms.

ScienceDirect.com - European Journal of Cancer - Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens

http://www.sciencedirect.com/science/article/pii/S0959804912006041


Sent from my iPhone

Lynch syndrome - review of patient testing

Discussion
Family history of colon cancer is documented for the majority of individuals although this varies by site. Very few individuals are tested for LS at any site, representing a potential under diagnosis of this hereditary condition in patients and their families. When testing is performed, there does not seem to be a preference for immunohistochemistry or microsatellite instability testing for any site.

http://www.google.ca/reader/i/?source=mog&hl=en&gl=ca#stream/user%2F16646332178603240200%2Fstate%2Fcom.google%2Freading-list


Sent from my iPhone

Journal of Ovarian Research | Abstract | High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer-open access

http://www.ovarianresearch.com/content/5/1/20/abstract

CMA touts one-on-one doctor-patient interaction over ‘gizmos’ - The Globe and Mail

From The Globe and Mail:
CMA touts one-on-one doctor-patient interaction over 'gizmos'

JCO: Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy

http://m.jco.ascopubs.org/content/early/2012/08/20/JCO.2011.39.8123.short?rss=1

Nearly half of U.S. doctors struggle with burnout: study

Nearly half of U.S. doctors struggle with burnout: study
http://www.reuters.com/article/idUSBRE87J0RJ20120821